INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinIART / S&P 90.66% / 15.20% |
LoseIART / S&P 1.60% / 15.00% |
LoseIART / S&P -98.62% / 50.40% |
| 2026-Q11/3 |
LoseIART / S&P -24.15% / -4.33% |
LoseIART / S&P 1.24% / 11.30% |
WinIART / S&P 1600.00% / 27.70% |
| 2025-Q41/3 |
LoseIART / S&P -13.33% / 2.65% |
LoseIART / S&P 1.53% / 9.00% |
WinIART / S&P 7377.78% / 13.40% |
| 2025-Q33/3 |
WinIART / S&P 16.79% / 8.12% |
WinIART / S&P 4.99% / 4.61% |
WinIART / S&P 7077.78% / 13.45% |
| 2025-Q20/3 |
LoseIART / S&P -44.20% / 10.94% |
LoseIART / S&P 3.53% / 4.83% |
LoseIART / S&P -2351.72% / 10.63% |
| 2025-Q12/3 |
WinIART / S&P -3.04% / -4.27% |
WinIART / S&P 6.19% / 4.98% |
LoseIART / S&P -176.00% / 10.57% |
| 2024-Q41/3 |
WinIART / S&P 24.82% / 2.41% |
LoseIART / S&P 4.47% / 5.25% |
LoseIART / S&P -110.84% / 6.15% |
| 2024-Q30/3 |
LoseIART / S&P -37.65% / 5.89% |
LoseIART / S&P 1.45% / 5.89% |
LoseIART / S&P -107.44% / 6.11% |
| 2024-Q20/3 |
LoseIART / S&P -17.80% / 4.28% |
LoseIART / S&P 1.37% / 5.38% |
LoseIART / S&P -81.53% / 5.12% |
| 2024-Q10/3 |
LoseIART / S&P -18.60% / 10.56% |
LoseIART / S&P -2.07% / 5.71% |
LoseIART / S&P -75.73% / 5.59% |
| 2023-Q41/3 |
WinIART / S&P 14.04% / 11.69% |
LoseIART / S&P -1.03% / 6.81% |
LoseIART / S&P -61.57% / 7.78% |
| 2023-Q30/3 |
LoseIART / S&P -7.15% / -3.27% |
LoseIART / S&P -1.44% / 7.52% |
LoseIART / S&P -41.26% / -5.03% |
| 2023-Q20/3 |
LoseIART / S&P -28.36% / 8.74% |
LoseIART / S&P -1.37% / 9.50% |
LoseIART / S&P -20.30% / -8.57% |
| 2023-Q11/3 |
LoseIART / S&P 2.39% / 7.50% |
LoseIART / S&P 0.18% / 10.77% |
WinIART / S&P 11.96% / -15.69% |
| 2022-Q42/3 |
WinIART / S&P 32.37% / 7.56% |
LoseIART / S&P 0.99% / 11.88% |
WinIART / S&P 9.09% / -17.99% |
| 2022-Q30/3 |
LoseIART / S&P -21.60% / -4.88% |
LoseIART / S&P 2.60% / 13.47% |
LoseIART / S&P -18.90% / -1.41% |
| 2022-Q21/3 |
WinIART / S&P -15.92% / -16.10% |
LoseIART / S&P 3.84% / 13.71% |
LoseIART / S&P -18.26% / 11.04% |
| 2022-Q11/3 |
WinIART / S&P -4.08% / -4.60% |
LoseIART / S&P 13.17% / 15.97% |
LoseIART / S&P -8.00% / 42.23% |
| 2021-Q40/3 |
LoseIART / S&P -2.18% / 11.03% |
LoseIART / S&P 12.43% / 15.00% |
LoseIART / S&P 25.32% / 96.40% |
| 2021-Q31/3 |
LoseIART / S&P 0.35% / 0.58% |
LoseIART / S&P 10.68% / 10.77% |
WinIART / S&P 279.10% / 69.42% |
| 2021-Q21/3 |
LoseIART / S&P -1.23% / 8.55% |
WinIART / S&P 8.78% / 6.58% |
LoseIART / S&P -8133.33% / 51.81% |
| 2021-Q12/3 |
WinIART / S&P 6.42% / 6.17% |
LoseIART / S&P -8.90% / -1.06% |
WinIART / S&P 545.16% / 7.39% |
| 2020-Q42/3 |
WinIART / S&P 37.48% / 12.15% |
LoseIART / S&P -9.60% / -3.72% |
WinIART / S&P 172.41% / -33.42% |
| 2020-Q31/3 |
LoseIART / S&P 0.49% / 8.93% |
LoseIART / S&P -8.46% / -2.04% |
WinIART / S&P -2.90% / -27.10% |
| 2020-Q20/3 |
LoseIART / S&P 5.19% / 20.54% |
LoseIART / S&P -7.05% / -0.46% |
LoseIART / S&P -102.59% / -27.11% |
| 2020-Q10/3 |
LoseIART / S&P -23.35% / -19.60% |
LoseIART / S&P 2.52% / 3.47% |
LoseIART / S&P -67.71% / -14.75% |
| 2019-Q40/3 |
LoseIART / S&P -2.98% / 9.07% |
LoseIART / S&P 3.06% / 5.36% |
LoseIART / S&P -19.44% / 2.99% |
| 2019-Q31/3 |
WinIART / S&P 7.56% / 1.70% |
LoseIART / S&P 3.29% / 5.02% |
LoseIART / S&P -30.30% / 0.21% |
| 2019-Q22/3 |
LoseIART / S&P 0.23% / 4.30% |
WinIART / S&P 8.89% / 6.64% |
WinIART / S&P 31.82% / 8.65% |
| 2019-Q12/3 |
WinIART / S&P 23.55% / 13.65% |
WinIART / S&P 14.64% / 8.12% |
LoseIART / S&P 9.09% / 14.29% |
| 2018-Q41/3 |
LoseIART / S&P -31.53% / -13.52% |
WinIART / S&P 23.92% / 9.05% |
LoseIART / S&P -12.20% / 18.23% |
| 2018-Q32/3 |
LoseIART / S&P 2.27% / 7.71% |
WinIART / S&P 35.57% / 10.21% |
WinIART / S&P 62.30% / 19.06% |
| 2018-Q22/3 |
WinIART / S&P 16.39% / 3.43% |
WinIART / S&P 30.94% / 9.03% |
LoseIART / S&P 7.32% / 14.46% |
| 2018-Q12/3 |
WinIART / S&P 15.63% / -0.76% |
WinIART / S&P 26.90% / 7.68% |
LoseIART / S&P 4.76% / 12.46% |
| 2017-Q41/3 |
LoseIART / S&P -5.19% / 6.64% |
WinIART / S&P 19.77% / 7.03% |
LoseIART / S&P -12.77% / 13.82% |
| 2017-Q30/3 |
LoseIART / S&P -7.39% / 4.48% |
LoseIART / S&P IART unavailable / 5.68% |
LoseIART / S&P -44.04% / 17.57% |
| 2017-Q21/3 |
WinIART / S&P 29.39% / 3.09% |
LoseIART / S&P IART unavailable / 4.83% |
LoseIART / S&P -1466.67% / 17.74% |
| 2017-Q10/3 |
LoseIART / S&P -1.78% / 6.07% |
LoseIART / S&P IART unavailable / 3.67% |
LoseIART / S&P -1150.00% / 13.32% |
| 2016-Q41/3 |
WinIART / S&P 3.92% / 3.82% |
LoseIART / S&P IART unavailable / 2.09% |
LoseIART / S&P -9500.00% / 7.05% |
| 2016-Q30/3 |
LoseIART / S&P 3.47% / 3.85% |
LoseIART / S&P IART unavailable / 0.20% |
LoseIART / S&P -318.00% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IART total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 11.37% | 20.78% |
| Annualized return | 11.37% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IART total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -77.83% | 83.14% |
| Annualized return | -26.01% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IART total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -61.17% | 319.30% |
| Annualized return | -9.03% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |